Erectile Dysfunction (ED) and Premature Ejaculation (PE): Treatment Overview

Erectile Dysfunction

Definition: Inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance (NIH Consensus Panel). Prevalence rises with age (~2% at 40-49 years to ~39% at ≥70 years) - Textbook of Family Medicine, p. 1260.

Mechanism: Erection depends on intact vascular, neurologic, endocrine, and psychological systems. Parasympathetic stimulation releases nitric oxide, raising cGMP in cavernosal smooth muscle and causing relaxation/engorgement; PDE-5 breaks down cGMP, so inhibiting it prolongs the erectile response - Textbook of Family Medicine, p. 1260.

First-line: Oral PDE-5 inhibitors

These are the first-line therapy for most men (SOR: A) - Textbook of Family Medicine, p. 1263.

Drug	Dose	Onset	Duration	Notes
Sildenafil (Viagra)	25-100 mg	30-60 min	3-5 hr	Reduced absorption with high-fat meals
Vardenafil (Levitra)	2.5-20 mg	30-120 min	4-5 hr	Reduced absorption with high-fat meals
Tadalafil (Cialis)	2.5-10 mg (daily or as needed)	16-30 min	24-72 hr	Longest acting; food doesn't affect absorption

Common side effects: headache, flushing, nasal congestion, dyspepsia, transient color-vision changes. Absolute contraindication: concurrent nitrate use (risk of severe hypotension) - and caution in men with recent MI/unstable cardiac disease, since ED often precedes overt cardiovascular disease and warrants cardiac risk assessment (Smith & Tanagho's General Urology, p. 629; Textbook of Family Medicine, p. 1263).

Lifestyle and reversible causes

Weight loss (≥10% body weight) and increased physical activity improve erectile scores in obese men; Mediterranean-style diet improves endothelial function.
Smoking cessation, limiting alcohol, treating diabetes/hypertension/dyslipidemia.
Reviewing medications that cause ED (beta-blockers, thiazides, SSRIs/TCAs, etc.) and switching class where feasible.
Correcting cycling-related perineal compression (saddle changes). (Smith and Tanagho's General Urology, p. 628-630)

Second-line options (if PDE-5 inhibitors fail or contraindicated)

Intracavernosal injection therapy (alprostadil) - effective, bypasses the need for neurologic/psychological arousal.
Intraurethral alprostadil.
Vacuum erection devices.
Testosterone replacement if hypogonadism is confirmed (testosterone <300 ng/dL) - improves libido more reliably than erectile function itself; options include IM injection, gels, patches, pellets, buccal (Textbook of Family Medicine, p. 1262).

Third-line

Penile prosthesis (implant) for refractory cases.
Psychosexual therapy - particularly valuable when psychogenic factors dominate; cognitive-behavioral approaches, couples therapy (Smith and Tanagho's General Urology, p. 629).

Recent evidence check

A 2025 systematic review found electrical stimulation (TENS-type approaches) shows some promise as an adjunct for ED but evidence remains limited (PMID 39962319), and a 2024 meta-analysis on platelet-rich plasma injections found only modest, low-certainty benefit (PMID 39541282) - neither is established standard-of-care yet; PDE-5 inhibitors remain first-line per a 2024 review of patient treatment preferences (PMID 38426421).

Premature Ejaculation

Definition: Ejaculation occurring before or shortly after vaginal penetration, generally defined as an intravaginal ejaculatory latency time (IELT) of ≤1 minute (DSM-5); lifelong vs. acquired subtypes exist. Using the DSM-5 cutoff, prevalence is only 1-3%, though up to 20-30% of men self-report "ejaculating faster than desired" - Textbook of Family Medicine, p. 1263; Campbell-Walsh Urology, p. 2081.

Pharmacologic treatment

Dapoxetine - a short-acting SSRI taken on-demand, FDA-approved (in many countries) specifically for PE; 30-60 mg improves perceived ejaculatory control in RCTs.
Other SSRIs (off-label) - e.g., paroxetine, sertraline - daily dosing prolongs the preorgasmic plateau and delays ejaculation, though these are used off-label for PE.
Topical anesthetics - lidocaine-prilocaine cream/spray applied to the glans reduces penile sensory stimulation and can increase IELT.
PDE-5 inhibitors added to SSRIs may give additional benefit, particularly when PE coexists with ED.
Tramadol has been studied but a large international RCT was stopped early over efficacy/safety concerns and it is not routinely recommended. (Textbook of Family Medicine, p. 1263-1264)

Non-pharmacologic

Behavioral techniques: stop-start method, squeeze technique.
Psychosexual/couples therapy - evidence is weak/inconsistent as monotherapy but can help address performance anxiety and relationship factors.
Treating underlying contributory conditions (e.g., prostatitis, hyperthyroidism).

Campbell-Walsh Urology's office management algorithm generally routes lifelong PE to pharmacotherapy as first-line, with psychosexual counseling as an adjunct.

Recent evidence check

A 2025 umbrella review of meta-analyses on PE pharmacotherapy confirms SSRIs (including dapoxetine), topical anesthetics, and PDE-5 inhibitor combinations have the best supporting evidence, while tramadol shows a less favorable safety profile (PMID 40326158). A 2025 meta-analysis found botulinum toxin-A injection is not effective for PE, so it should not be recommended despite some earlier interest (PMID 39870913).

Practical takeaway

ED: start with lifestyle optimization + PDE-5 inhibitor (sildenafil/tadalafil/vardenafil), assess cardiovascular risk and screen for nitrate use before prescribing; escalate to intracavernosal injection, vacuum device, or prosthesis if oral therapy fails.
PE: on-demand dapoxetine (or off-label SSRI) and/or topical lidocaine-prilocaine, combined with behavioral techniques (stop-start/squeeze) and counseling; avoid tramadol and botulinum toxin given weak/negative evidence.

If either condition is refractory to first-line measures, or there are red flags (chest pain, sudden-onset severe ED, penile pain/curvature, hormonal signs), referral to urology or endocrinology is warranted.

This is a shared conversation. Sign in to Orris to start your own chat.